Vasileios Kyttaris, MD
Rheumatology · Boston, MANPI 1851344139
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,248 of the $32,918 with a category attached, or 79.7%. 15 manufacturers reported payments, led by AstraZeneca at 45.2% of the total. 2025 is the largest year on record at $8,667, more than ten times the $829 reported in 2019.
Across 55 payments — averaging $598.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- GSK$5K
- Boehringer Ingelheim$3K
- Aurinia Pharma U.S., Inc.$3K
- Astrazeneca UK Limited$3K
- Johnson & Johnson$2K
- plus $3K from 9 others
Across 112 payments — averaging $7135.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$555K
- AbbVie$137K
- Takeda Pharmaceuticals U.S.A., Inc.$45K
- Astrazeneca UK Limited$25K
- E.r. Squibb & Sons, L.L.C.$20K
- Eli Lilly$16K
- plus $2K from 1 others
What the payments were for
- Consulting fees$26,24880%
- Speaking & faculty fees$2,5208%
- Travel & lodging$2,2887%
- Food & beverage$1,7635%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $14,888 |
| GSK | 10 | $5,075 |
| Boehringer Ingelheim | 4 | $3,352 |
| Aurinia Pharma U.S., Inc. | 3 | $2,759 |
| Astrazeneca UK Limited | 14 | $2,508 |
| Johnson & Johnson | 3 | $1,772 |
| Janssen Scientific Affairs, LLC | 3 | $1,236 |
| Fresenius Kabi USA, LLC | 1 | $360 |
| Vertex | 1 | $295 |
| E.r. Squibb & Sons, L.L.C. | 1 | $222 |
| AbbVie | 1 | $125 |
| Pfizer | 1 | $103 |
| Cardinal Health 110 LLC | 1 | $100 |
| Genentech USA, Inc. | 1 | $99 |
| Amgen | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,918 in reported general payments places this provider in the 85th percentile of 265 rheumatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 60 | $402,267 |
| Enbrel SureclickEtanercept | 55 | $401,437 |
| Humira(Cf) PenAdalimumab | 36 | $325,328 |
| Humira PenAdalimumab | 15 | $185,407 |
| Orencia ClickjectAbatacept | 33 | $182,388 |
| Cosentyx Unoready PenSecukinumab | 23 | $157,818 |
| Taltz Autoinjector (2 Pack)Ixekizumab | 11 | $145,727 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 11 | $105,758 |
| ActemraTocilizumab | 35 | $99,177 |
| Actemra ActpenTocilizumab | 14 | $51,241 |
| Mycophenolic AcidMycophenolate Sodium | 31 | $5,208 |
| Cevimeline Hcl | 26 | $3,495 |
| MethotrexateMethotrexate Sodium | 154 | $3,008 |
| Allopurinol | 39 | $2,625 |
| Colchicine | 19 | $1,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $125 | $402,26760 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 265 rheumatology providers in Massachusetts.
Other rheumatology in Boston
- Marilyn PikeBoston$1.4M
- John StoneBoston$926K
- Lee SimonBoston$600K
- Jeffrey SparksBoston$299K
- Tanya LaidlawBoston$244K
- Tuhina NeogiBoston$242K
- Michael WeinblattBoston$228K
- Michael BrennerBoston$115K
- Zachary WallaceBoston$106K
- Flavia CastelinoBoston$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.